Quantum BioPharma plans debt conversion at conversion price of CAD 4 per share
QNTM•Separate debt settlement with creditors
Separately, the company said it plans a debt settlement with creditors through share issuance at a deemed price equal to the CAD 4 conversion price.
Planned private placement of secured convertible debentures
Quantum BioPharma outlined terms for secured convertible debentures in a planned private placement, including quarterly cash interest starting June 30, 2026.
The debentures carry 1.25% monthly interest and mature 24 months from issuance. Principal or accrued interest may be converted at a price of CAD 4 per share.
